Clinical trials: BCLC Stage B Hepatocellular Carcinoma
Hepatocellular Carcinoma
Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody for patients with intermediate-stage hepatocellular carcinoma (HCC) beyond up-to-seven criteria
- Trial name
- NCT03775707
- Testing
- Lenvatinib, PD-1 antibody
- Where
- China
- Sponsor
- Shi Ming
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
This phase II trial tests whether nivolumab and ipilimumab works to shrink tumors in patients with liver cancer that has spread to nearby tissue or lymph nodes (locally advanced), has spread to other places in the body…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT05199285
- Testing
- Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Academic and Community Cancer Research United
Hepatocellular Carcinoma
The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study
This study is a single-center, single-arm, open-label prospective clinical trial. By recording the disease-free progression (PFS), overall survival (OS) and tumor treatment response of the included patients, it is planned to…
- Trial name
- NCT04909866
- Testing
- TACE+Lenvatininb+Camrelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hepatocellular Carcinoma
Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients
It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE combined with Camrelizumab in the treatment of patients with BCLC stage B and C HCC.Treatment will continue until disease progression or…
- Trial name
- NCT04483284
- Testing
- TACE combined with Camrelizumab, TACE plus Camrelizumab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Zhongshan Hospital
Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
The objective of this pivotal study is to evaluate the safety and effectiveness of SIRT using SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC in patients with Barcelona Clinic Liver Cancer…
- Conditions
- Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
- Trial name
- DOORwaY90 (NCT04736121)
- Testing
- Resin microspheres containing yttrium-90 (Y-90)
- Where
- 22 sites in United States
- Volunteers
- 100 people
- Sponsor
- Sirtex Medical
BCLC Stage B Hepatocellular Carcinoma
Real-World Treatment Patterns and Survival Outcomes in Patients With Intermediate-Stage Hepatocellular Carcinoma.
The goal of this observational study is to learn about the different treatment options for intermediate-stage hepatocellular carcinoma.
- Trial name
- NCT07449637
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Sohag University
Hepatocellular Carcinoma by BCLC Stage
Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions
Liver cancer is the third leading cause of cancer-related deaths worldwide. The majority of primary liver cancers occur as hepatocellular carcinoma (HCC), the incidence of which is increasing in many parts of the world.
- Trial name
- HESTIA (NCT05622071)
- Testing
- Tislelizumab
- Where
- 10 sites in France
- Volunteers
- 50 people
- Sponsor
- UNICANCER
Barcelona Clinic Liver Cancer (BCLC) Stage A, B or C HCC
DNP-MRSI of HCC Metabolism to Predict Therapeutic Response
This proposal describes a non-therapeutic diagnostic clinical trial to estimate the ability of DNP-MRS imaging of hyperpolarized 1-13C-pyruvate uptake and metabolism to predict response following LRT with TACE/TARE/Microwave…
- Trial name
- NCT07807475
- Testing
- Hyperpolarized 1-13C -Pyruvate
- Volunteers
- 232 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
HCC, Radiofrequency Ablation
Combined Treatment of RFA and Sorafenib on Recurrent HCC
RFA is a routaine treatment of recurrent HCC. Recently Sorafenib was reported to be a promising drug to treat late stage HCC. But few studies were related with its effectiveness on recurrent HCC.
- Conditions
- HCC, Radiofrequency Ablation, Sorafenib
- Trial name
- REPEAT (NCT01470495)
- Testing
- RFA + Sorafenib, RFA
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Southwest Hospital, China
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
This will be a Phase II study investigating single agent pembrolizumab (Keytruda®) as a second-line therapy for subjects with hepatocellular carcinoma (HCC) who either progressed on or after sorafenib or did not tolerate…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection, Refractory Liver Carcinoma
- Trial name
- NCT02940496
- Testing
- Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy
To compare the impact on survival of neo-adjuvant TAI for patients with beyond Milan criteria BCLC stage A/B HCC who underwent hepatectomy.
- Trial name
- NCT03851913
- Testing
- TAI
- Where
- China
- Volunteers
- 344 people
- Sponsor
- Sun Yat-sen University
Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
This early phase I trial evaluates the side effects of BO-112 and pembrolizumab and how well they work in treating patients with Barcelona Clinic Liver Cancer (BCLC) stage B or C liver cancer.
- Conditions
- Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma
- Trial name
- NCT04777708
- Testing
- Nanoplexed Poly I:C BO-112, Pembrolizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Hepatocellular Carcinoma, Liver Cancer
Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma
Rationale: Patients diagnosed with hepatocellular carcinoma (HCC) at an intermediate or advanced stage (according to the BCLC classification system) are not amenable of curative treatment.
- Trial name
- NCT00910572
- Testing
- Yttrium-90 microspheres (Therasphere MDS Nordion)
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Hepatocellular Carcinoma
Neo-TACE-HAIC for BCLC B Stage HCC
Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. Although BCLC (Barcelona clinical liver cancer) system recommend to transarterial chemoembolization (TACE) for BCLC B stage patients, increasing…
- Trial name
- NeoconceptB (NCT04424043)
- Testing
- neo-TACE-HAIC+Surgery, Surgery alone
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Sun Yat-sen University
Advanced Hepatocellular Carcinoma
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
The aim of this study is to compare the efficacy and safety of YIV-906 plus standard-of-care sorafenib versus those of sorafenib alone as a first-line systemic treatment for patients with Hepatitis B (+) associated advanced…
- Trial name
- NCT04000737
- Testing
- Sorafenib+YIV-906
- Where
- 24 sites in United States, China and 2 more
- Volunteers
- 62 people
- Sponsor
- Yiviva Inc.
HCC - Hepatocellular Carcinoma, Tremelimumab
Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Tremelimumab plus durvalumab (the STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC); however, it demonstrates limited efficacy, with an objective response rate (ORR) of only 20.1%.
- Conditions
- HCC - Hepatocellular Carcinoma, Tremelimumab, Durvalumab, Radiotherapy
- Trial name
- Photon-STRIDE (NCT06999707)
- Testing
- Photon radiotherapy, Tremelimumab, Durvalumab
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy
SIRT and Peri-immunotherapy : a New Concept
The combination of selective internal radiation therapy (SIRT) with immunotherapy represents an innovative and potentially highly effective therapeutic strategy for the treatment of advanced-stage hepatocellular carcinoma (BCLC…
- Trial name
- IMSIRT (NCT06971237)
- Testing
- Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization, Atezolizumab ± Bevacizumab
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
The purpose of this study is to evaluate the safety and efficacy of the combination therapy with HAIC-TACE and donafenib compared to TACE plus donafenib in patients with BCLC B stage unresectable hepatocellular carcinoma (HCC)…
- Trial name
- NCT05171166
- Testing
- HAIC, TACE, FOLFOX
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University
Hepatocellular Carcinoma (HCC)
Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
Dear Sir/Madam, We would like to invite you to participate in this clinical research, which has been approved by the Medical Ethics Committee of Zhejiang Cancer Hospital.
- Trial name
- HAICI (NCT06741020)
- Testing
- Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma (HCC)
Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
This study is a prospective, single-arm, phase Ⅱtrial. The subjects are patients resectable centrally-located hepatocellular carcinoma in BCLC stage B who are admitted to the Hepatobiliary Surgery Department of Tongji Hospital …
- Trial name
- NCT07154082
- Testing
- TACE (transarterial chemoembolization) combined with targeted/immunotherapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Wei Zhang